What one share of Context Therapeutics holds
We are a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies (“bsAb”) for solid tumors. Our goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (“CLDN6”) x CD3 TCE, CT-95, a Mesothelin (“MSLN”) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (“Nectin-4”) x CD3 TCE.
Context Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.48 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.36 |
| Cash and investments | $0.47 |
| Book value | $0.42 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$3.96 | — | — | — | — |
| 2021 | — | −$3.69 | $0.00 | −$3.11 | — | — |
| 2022 | — | −$0.93 | $0.00 | −$0.85 | — | $2.18 |
| 2023 | — | −$1.50 | $0.00 | −$1.32 | — | $0.74 |
| 2024 | — | −$0.46 | $0.00 | −$0.25 | — | $1.06 |
| 2025 | — | −$0.38 | $0.00 | −$0.28 | — | $0.66 |
Common questions about Context Therapeutics
How much does one share of Context Therapeutics earn?
Over the last 12 months, Context Therapeutics lost $0.48 for each share.
Does Context Therapeutics pay a dividend?
Context Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Context Therapeutics’s book value per share?
Context Therapeutics’s book value is $0.42 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Context Therapeutics have?
Each share of Context Therapeutics has $0.47 of cash and investments, as of June 30, 2026.
What is Context Therapeutics’s free cash flow per share?
−$0.36 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Context Therapeutics bought back shares?
Context Therapeutics’s share count rose about 4532% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.